<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1302244916
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NEUPRO 6 mg/24 hrs Transdermal Patches
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROTIGOTINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Transdermal use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Transdermal patch
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Patch
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        296.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LTS LOHMANN Therapie-Systeme" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LTS LOHMANN Therapie-Systeme
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                             UCB Pharma S.A.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N04BC09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>What Neupro is and what it is used for</strong></p><p>&nbsp;</p><p><strong>What Neupro is</strong></p><p>Neupro contains the active substance rotigotine.</p><p>&nbsp;</p><p>It belongs to a group of medicines called &lsquo;dopamine agonists&rsquo;. Dopamine is a messenger in the brain which is important for movement</p><p>&nbsp;</p><p><strong>What Neupro is used for</strong></p><p>Neupro is used in adults to treat the signs and symptoms of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Parkinson&rsquo;s</strong><strong> disease</strong> &ndash; Neupro can be used on its own or with another medicine called levodopa.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>What you need to know before you use Neupro</strong></p><p>&nbsp;</p><p><strong>Do not use Neupro if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are <strong>allergic</strong> to <strong>rotigotine</strong> or any of the <strong>other ingredients</strong> of this medicine (listed in section&nbsp;6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you need to have a <strong>magnetic resonance imaging </strong>(MRI) scan (diagnostic pictures of the inside of the body, created using magnetic rather than x-ray energy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you need &lsquo;<strong>cardioversion</strong>&rsquo; (specific treatment for abnormal heart beat).</p><p>&nbsp;</p><p>You must take your Neupro patch off just before undergoing magnetic resonance imaging (MRI) or cardioversion to avoid skin burns because the patch contains aluminium. You can put a new patch on afterwards.</p><p>&nbsp;</p><p>If any of the above apply to you, do not use Neupro. If you are not sure about this, talk to your doctor or pharmacist first.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before using Neupro. This is because:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your <strong>blood pressure</strong> needs checking regularly while using Neupro, especially at the start of the treatment. Neupro may affect your blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your <strong>eyes</strong> need checking regularly while using Neupro. If you notice any problems with your eyesight between checks, talk to your doctor straight away.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have serious <strong>liver problems</strong>, your doctor may need to change the dose. If your liver problems get worse during treatment, talk to your doctor straight away.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you may get <strong>skin problems</strong> caused by the patch &ndash; see &lsquo;<strong>Skin problems caused by the patch</strong>&rsquo; in section&nbsp;4.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you may <strong>feel very sleepy</strong> or <strong>fall asleep suddenly</strong> &ndash; see &lsquo;<strong>Driving and using machines</strong>&rsquo; in section&nbsp;2.</p><p><strong>&nbsp;</strong></p><p>If you experience these symptoms after beginning treatment with Neupro, contact your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>Loss of consciousness can occur</strong></p><p>Neupro can cause loss of consciousness. This can happen especially when you start using Neupro or when your dose is increased. Tell your doctor if you lose consciousness or feel dizzy.</p><p><strong>&nbsp;</strong></p><p><strong>Changes in behaviour and abnormal thinking</strong></p><p>&nbsp;</p><p>Neupro can cause side effects that change your behaviour (how you act). You may find it helpful to tell a member of your family or carer that you are using this medicine and ask them to read this leaflet. This is so that your family or carer can tell you, or your doctor, if they are worried about any changes in your behaviour.<br />&nbsp;</p><p>These include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual urges or cravings which you cannot resist and that could harm yourself or others</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal thinking or behaviour.</p><p>&nbsp;</p><p>See &lsquo;<strong>Changes to your behaviour and abnormal thinking</strong>&rsquo; in section&nbsp;4 for more information.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Do <strong>not</strong> give this medicine to <strong>children</strong> below 18&nbsp;years of age because it is not known if it is safe or effective in this age group.</p><p>&nbsp;</p><p><strong>Other medicines and Neupro</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription and herbal medicines.</p><p>&nbsp;</p><p>If you are treated with Neupro and levodopa at the same time, some side effects may get more serious. This includes seeing or hearing things that are not real (hallucinations), movements you cannot control related to Parkinson&rsquo;s disease (&lsquo;dyskinesia&rsquo;), and swelling of legs and feet.</p><p>&nbsp;</p><p>Do not take the following medicines while using Neupro &ndash; because they may decrease its effect:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lsquo;anti‑psychotic&rsquo; medicines &ndash; used to treat certain mental illnesses</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; metoclopramide &ndash; used to treat nausea (feeling sick) and vomiting.</p><p>&nbsp;</p><p>Talk to your doctor before using Neupro if you are taking:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sedating medicines such as benzodiazepines or medicines used to treat mental illness or depression.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that lower blood pressure. Neupro may decrease blood pressure when you stand up &ndash; this effect may be worsened by the medicines used to lower blood pressure.</p><p>&nbsp;</p><p>Your doctor will let you know if it is safe to keep taking these medicines while using Neupro.</p><p>&nbsp;</p><p><strong>Neupro</strong><strong> with food, drink and alcohol</strong></p><p>Because rotigotine enters your bloodstream through your skin, food or drink does not affect the way this medicine is absorbed by the body. You should discuss with your doctor if it is safe for you to drink alcohol while using Neupro.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Do not use Neupro if you are pregnant. This is because the effects of rotigotine on pregnancy and the unborn baby are not known.</p><p>&nbsp;</p><p>Do not breast-feed during treatment with Neupro. This is because rotigotine may pass into your breast milk and affect your baby. It is also likely to lower the amount of milk you produce.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Neupro may make you feel very sleepy, and you may fall asleep very suddenly. If this happens, do not drive. In isolated cases, people have fallen asleep while driving and this has caused accidents.</p><p>&nbsp;</p><p>Also do not use tools or machines if you feel very sleepy &ndash; or do anything else which may put others or yourself at risk of serious injury.</p><p>&nbsp;</p><p><strong>Neupro contains sodium metabisulphite (E223)</strong></p><p>Sodium metabisulphite (E223) may rarely cause severe hypersensitivity (allergic) reactions and bronchospasm (breathing distress caused by narrowing of the airways).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to use Neupro</strong></p><p>&nbsp;</p><p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>&nbsp;</strong></p><p><strong>Which strength patches to use</strong></p><p>The dose of Neupro will depend on your illness &ndash; see below.</p><p>&nbsp;</p><p>Neupro is available in different strength patches which release the medicine over 24&nbsp;hours. The strengths are 2&nbsp;mg/24<em>&nbsp;</em>h, 4&nbsp;mg/24<em>&nbsp;</em>h, 6&nbsp;mg/24&nbsp;h and 8&nbsp;mg/24&nbsp;h for the treatment of Parkinson&rsquo;s disease.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may have to use more than one patch to reach your dose, as prescribed by your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For doses higher than 8 mg/24 h (doses prescribed by your doctor above the available strengths), multiple patches must be applied to achieve the final dose. For example a daily dose of 10 mg/24 h may be reached by applying one patch of 6 mg/24 h and one patch of 4 mg/24 h.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The patches should not be cut into pieces.</p><p>&nbsp;</p><p><strong>Treatment of Parkinson&rsquo;s disease</strong></p><p><strong>Patients not taking levodopa </strong><strong>&ndash;</strong><strong> early stage of Parkinson&rsquo;s disease</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your starting daily dose will be one 2&nbsp;mg/24&nbsp;h patch each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; From the second week your daily dose may be increased by 2&nbsp;mg each week &ndash; until you get to the right maintenance dose for you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For most patients, the right dose is between 6&nbsp;mg and 8&nbsp;mg each day. This is normally reached within 3 to 4&nbsp;weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The maximum dose is 8&nbsp;mg each day.</p><p>&nbsp;</p><p><strong>Patients taking levodopa </strong><strong>&ndash;</strong><strong> advanced stage of Parkinson&rsquo;s disease</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your starting daily dose will be one 4&nbsp;mg/24&nbsp;h patch each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; From the second week your daily dose will be increased by 2&nbsp;mg each week &ndash; until you get to the right maintenance dose for you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For most patients, the right dose is between 8&nbsp;mg and 16&nbsp;mg each day. This is normally reached within 3 to 7&nbsp;weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The maximum dose is 16&nbsp;mg each day.</p><p>&nbsp;</p><p>If you have to stop taking this medicine, see <strong>&lsquo;If you stop using Neupro&rsquo;</strong> in section&nbsp;3.</p><p>&nbsp;</p><p><strong>How to use the Neupro patches</strong></p><p>Neupro is a patch that is put on the skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Make sure that you take the old patch off before putting on a new one.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stick the new patch on <strong>a</strong> <strong>different area of the skin each day</strong>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leave the patch on your skin for 24&nbsp;hours, then take it off and put on a new one.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Change the patches</strong> at about the <strong>same time every day</strong>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not cut the Neupro patches into pieces.</strong></p><p>&nbsp;</p><p><strong>Where to stick the patch</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Put the sticky side of the patch onto clean, dry,<br />healthy skin on the following areas as shown in grey on the pictures below:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shoulder or upper arm.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Belly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flank (your side, between the ribs<br />and hips).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thigh or hip.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>To avoid skin irritation&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stick the patch onto a <strong>different area of skin each day</strong>. For example, put it on the right side of your body one day, then on the left side of your body the next day. Or on your upper body one day, then on your lower body the day after that.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do <strong>not</strong> stick Neupro on the <strong>same area of skin</strong> twice <strong>within 14&nbsp;days</strong>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do <strong>not</strong> stick the patch on <strong>broken or damaged skin</strong> &ndash; or on skin that is <strong>red or irritated</strong>.</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>If you still get problems with your skin because of the patch, please see <strong>Skin problems caused by the patch&rsquo;</strong> in section&nbsp;4 for more information.</p><p>&nbsp;</p><p>To <strong>prevent the patch becoming loose or falling off</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do <strong>not</strong> put the patch in an area where it can be <strong>rubbed by tight clothing</strong>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do <strong>not </strong>use <strong>creams, oils, lotions, powders </strong>or other <strong>skin products</strong> where you will put the patch. Also do not use them on or near a patch you are already wearing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you need to stick the patch to a hairy area of skin, you must <strong>shave</strong> the area at least <strong>3&nbsp;days before</strong> sticking the patch there.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the edges of the patch lift, the patch may be taped down with adhesive medical tape.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>If the patch falls off, put on a new patch for the rest of the day &ndash; then replace the patch at the usual time.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do <strong>not</strong> let the area of the patch <strong>get hot</strong> &ndash; for example too much sunlight, saunas, hot baths, heating pads or hot-water bottles. This is because the medicine may be released faster. If you think that too much heat has been applied, contact your doctor or pharmacist.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always check that the patch has not fallen off after activities such as <strong>bathing, showering or exercising.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the patch has <strong>irritated your skin, keep</strong> that area <strong>protected from direct sunlight</strong>. This is because it may change the colour of the skin.</p><p>&nbsp;</p><p><strong>How to use the patch</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each patch is packed in a separate sachet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before opening the sachet decide where you are going to stick this new patch and check you have removed any old patch.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stick the Neupro patch onto your skin as soon as you have opened the sachet and removed the release liner.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>1</strong>.<br />To open the sachet, hold the sachet in both hands.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>2. </strong></p><p>Peel apart the foil.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>3.</strong><br />Open the sachet.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>4.</strong><br />Take the patch out of the sachet.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>5.</strong></p><p>The sticky side of the patch is covered by a transparent release liner.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the patch in both hands with the release liner facing you.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>6.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bend the patch in half.</p><p>This makes the S-shaped break in the liner open up.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>7.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peel off one side of the release liner.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not touch the sticky side of the patch with your fingers.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>8.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the other half of the rigid release liner.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Then put the sticky half of the patch onto your skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Press the sticky side of the patch firmly into place.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>9.</strong><br />Fold back the other half of the patch and remove the other side of the release liner.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>10.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Press the patch down firmly with the palm of your hand.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep it pressed for about 30&nbsp;seconds.</p><p>This makes sure the patch is touching the skin and the edges stick down well.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>11.</strong></p><p>Wash your hands with soap and water straight after handling the patch.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>How to take off a used patch</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slowly and carefully peel off the used patch.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently wash the area with warm water and mild soap. This will remove any stickiness that stays on your skin. You can also use a little baby oil to remove any stickiness that will not wash off.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use alcohol or other dissolving liquids &ndash; such as nail polish remover. These may irritate your skin.</p><p>&nbsp;</p><p><strong>If you use more Neupro than you should</strong></p><p>Using higher doses of Neupro than your doctor has prescribed may cause side effects such as feeling sick (nausea) or vomiting, low blood pressure, seeing or hearing things that are not real (hallucinations), feeling confused, very sleepy, having involuntary movements and convulsions.</p><p>In such cases, contact your doctor or hospital straight away. They will tell you what to do.</p><p>&nbsp;</p><p><strong>If you forget to change the patch at your usual time</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have forgotten to change the patch at your usual time, change it as soon as you remember. Take off the old patch and use a new one.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have forgotten to stick on a new patch after removing the old one, use a new patch as soon as you remember.</p><p>&nbsp;</p><p>In both cases, use a new patch at the usual time on the following day. Do not use a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop using Neupro</strong></p><p>Do not stop using Neupro without talking to your doctor. A sudden stop could lead to a medical condition called &lsquo;neuroleptic malignant syndrome&rsquo; which could be life-threatening. The signs include: loss of muscle movement (akinesia), rigid muscles, fever, unstable blood pressure, increased heart rate (tachycardia), confusion, low level of consciousness (such as a coma).</p><p>&nbsp;</p><p>If your doctor says you should stop Neupro, the <strong>daily dose</strong> should be <strong>lowered gradually:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Parkinson&rsquo;s disease</strong> &ndash; lowered by 2&nbsp;mg every other day.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</strong></p><p>&nbsp;</p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Tell your doctor or pharmacist if you notice any side effects.</p><p>&nbsp;</p><p><strong>Side effects more likely at the start of treatment</strong></p><p>You may <strong>feel sick</strong> (nausea) and <strong>vomit</strong> <strong>at the start of treatment</strong>. These effects are usually mild or moderate and only last for a short time. <strong>Talk to your doctor</strong> if they last for a long time or if you are worried about them.</p><p>&nbsp;</p><p><strong>Skin problems caused by the patch</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may get redness and itching on the skin where the patch has been &ndash; these reactions are usually mild or moderate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The reactions normally go away after a few hours &ndash; once you remove the patch.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Talk to your doctor </strong>if you have a skin reaction that lasts longer than a few days or is severe. Also do this if it spreads outside the area of skin that was covered by the patch.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avoid sunlight and solarium exposure on areas of skin showing any kind of skin reaction caused by the patch.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To help avoid the skin reactions, you should put the patch on a different area of skin every day, and only use the same area again after 14&nbsp;days.</p><p>&nbsp;</p><p><strong>Loss of consciousness can occur</strong></p><p>Neupro can cause loss of consciousness. This can happen especially when you start using Neupro or when your dose is increased. Tell your doctor if you lose consciousness or feel dizzy.</p><p><strong>&nbsp;</strong></p><p><strong>Changes in behaviour and abnormal thinking</strong></p><p><strong>Tell your doctor if you notice any changes in behaviour, thinking or both, that are listed below. They will discuss ways of managing or reducing symptoms. </strong></p><p>&nbsp;</p><p>You may find it helpful to also tell a member of your family or carer that you are using this medicine and ask them to read this leaflet. This is so that your family or carer can tell you, or your doctor, if they are worried about any changes in your behaviour. Neupro can cause unusual urges or cravings which you cannot resist such as the impulse, drive or temptation to do things that could harm yourself or others.</p><p><strong>&nbsp;</strong></p><p>These may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; strong impulse to gamble too much &ndash; even if this seriously affects you or your family</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; altered or increased sexual interest and behaviour which causes significant concern to you or others &ndash; for example, an increased sex drive</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uncontrolled shopping or spending too much</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; binge eating (eating large amounts of food in a short period of time) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger).</p><p>&nbsp;</p><p>Neupro may cause other behaviours and abnormal thinking. These may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal thoughts about reality</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; delusions and hallucinations (seeing or hearing things that are not real)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorientation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aggressive behaviour</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; agitation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; delirium.</p><p><strong>&nbsp;</strong></p><p><strong>Tell your doctor if you notice any changes in behaviour, thinking or both that are listed above. They will discuss ways of managing or reducing symptoms. </strong></p><p><u>&nbsp;</u></p><p><strong>Allergic reactions</strong></p><p>Contact your doctor if you notice signs of an allergic reaction &ndash; these can include swelling of the face, tongue or lips.</p><p>&nbsp;</p><p><strong>Side effects when using Neupro for Parkinson&rsquo;s disease</strong></p><p>Tell your doctor, pharmacist or nurse if you get any of the following side effects:</p><p><strong>&nbsp;</strong></p><p><strong>Very common</strong>: may affect more than 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sleepy or dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea), vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin reactions under the patch such as redness and itching</p><p><strong>&nbsp;</strong></p><p><strong>Common</strong>: may affect up to 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; falling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hiccups</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of legs and feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak (fatigue), feeling tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of heartbeat (palpitation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation, dry mouth, heartburn</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness, increased sweating, itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vertigo (sensation of whirling motion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seeing or hearing things that are not real (hallucinations)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure when standing up, high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty falling asleep, sleep disorder, difficulty sleeping, nightmare, unusual dreams</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; movements you cannot control related to Parkinson&rsquo;s disease (dyskinesia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting, feeling dizzy when standing up because of fall in blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unable to resist the impulse to perform an action that is harmful involving excessive gambling, repetitive meaningless actions, uncontrolled shopping or spending too much</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; binge eating (eating large amount of food in a short period of time), compulsive eating (eating more food than normal and more than needed to satisfy hunger)</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon</strong>: may affect up to 1 in 100 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight increase</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased heart rate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sex drive</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach discomfort and pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; generalised itching, skin irritation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; falling asleep suddenly without warning</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unable to achieve or maintain an erection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling agitated, disorientated, confused or paranoid</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased or abnormal liver test results</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sight problems such as seeing colours or lights</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of creatine phosphokinase (CPK) in blood in Japanese patients (CPK is an enzyme found mainly in skeletal muscles), no information is available in other populations.</p><p><strong>&nbsp;</strong></p><p><strong>Rare</strong>: may affect up to 1 in 1,000 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; delusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; delirium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling irritable</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being aggressive</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; psychotic disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash over larger parts of the body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; involuntary muscle spasms (convulsion)</p><p><strong>&nbsp;</strong></p><p><strong>Not known</strong>: it is not known how often these happen</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; craving large doses of medicines like Neupro &ndash; more than needed for the illness. This is known as &lsquo;dopamine dysregulation syndrome&rsquo; and can lead to use of too much Neupro.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dropped head syndrome</p><p>&nbsp;</p><p>Tell your doctor, pharmacist or nurse if you notice any of the side effects listed above.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed at the end of this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>How to store Neupro</strong></p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label and box.</p><p>&nbsp;</p><p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p><strong>What to do with the used and unused patches</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Used patches still contain the active substance &lsquo;rotigotine&rsquo;, which may be harmful to others. Fold the used patch with the sticky side inwards. Put the patch in the original sachet and then throw it away safely, out of the reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and other information</strong></p><p>&nbsp;</p><p><strong>What Neupro contains</strong></p><p>The active substance is rotigotine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2&nbsp;mg/24&nbsp;h:</p><p>Each patch releases 2 mg of rotigotine per 24 hours. Each patch of 10 cm<sup>2</sup> contains 4.5 mg of rotigotine.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4&nbsp;mg/24&nbsp;h:</p><p>Each patch releases 4&nbsp;mg of rotigotine per 24&nbsp;hours. Each patch of 20&nbsp;cm<sup>2</sup> contains 9.0&nbsp;mg of rotigotine.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6&nbsp;mg/24&nbsp;h:</p><p>Each patch releases 6&nbsp;mg of rotigotine per 24&nbsp;hours. Each patch of 30&nbsp;cm<sup>2</sup> contains 13.5&nbsp;mg of rotigotine.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8&nbsp;mg/24&nbsp;h:</p><p>Each patch releases 8&nbsp;mg of rotigotine per 24&nbsp;hours. Each patch of 40&nbsp;cm<sup>2</sup> contains 18.0&nbsp;mg of rotigotine.</p><p>&nbsp;</p><p>The other ingredients are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Poly(dimethylsiloxane, trimethylsilyl silicate)‑copolymerisate, povidoneK90, sodium metabisulphite (E223), ascorbyl palmitate (E304) and DL‑&alpha;‑tocopherol (E307).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Backing layer: Polyester film, siliconized, aluminized, colour coated with a pigment (titanium dioxide (E171), pigment yellow&nbsp;95, pigment red&nbsp;166) layer and imprinted (pigment red&nbsp;144, pigment yellow&nbsp;95, pigment black&nbsp;7).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Release liner: Transparent fluoropolymer coated polyester film.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Neupro looks like and contents of the pack</strong></p><p>Neupro is a transdermal patch. It is thin and has three layers. It is square-shaped with rounded edges. The outside is tan-coloured and is imprinted with Neupro 2 mg/24 h, Neupro 4&nbsp;mg/24&nbsp;h, Neupro 6&nbsp;mg/24&nbsp;h or Neupro 8&nbsp;mg/&nbsp;24 h.</p><p>&nbsp;</p><p>Neupro is available in the following pack-sizes:</p><p>Boxes containing 7or 28 patches, which are individually sealed in sachets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What Neupro looks like and contents of the pack
	Neupro is a transdermal patch. It is thin and has three layers. It is square-shaped with rounded edges. The outside is tan-coloured and is imprinted with Neupro 2 mg/24 h, Neupro 4 mg/24 h, Neupro 6 mg/24 h or Neupro 8 mg/ 24 h.
	
	Neupro is available in the following pack-sizes:
	Boxes containing 7or 28 patches, which are individually sealed in sachets.
	
	Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by</strong></p><p>&nbsp;</p><p>LTS Lohmann Therapie-Systeme AG,</p><p>Lohmannstrase 2, D-56626 Andernach, Germany</p><p><strong>&nbsp;</strong></p><p><strong>Batch Release Site</strong></p><p>&nbsp;</p><p>UCB Pharma S.A.</p><p>Chemin du Foriest</p><p>B-1420 Braine l&rsquo;Alleud</p><p>Belgium</p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder </strong></p><p>&nbsp;</p><p>UCB Pharma S.A.</p><p>All&eacute;e de la Recherche 60</p><p>B-1070 Bruxelles</p><p>Belgium</p><p>&nbsp;</p><p>&nbsp;</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                {06/2018}
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ما دواء نيوبرو؟ وفيم يُستخدم؟</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما دواء نيوبرو؟</strong></p><p dir="RTL">يحتوي دواء نيوبرو على المادة الفعّالة روتيجوتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">فهو ينتمي إلى مجموعة من الأدوية تسمى &quot;ناهضات الدوبامين&quot;. يُعد الدُّوبامِين أحد الناقلات الموجودة بالمخ وهو هام للحركة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فيمَ يُستخدم دواء نيوبرو؟</strong></p><p dir="RTL">يُستخدم دواء نيوبرو في البالغين لعلاج علامات وأعراض الآتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مرض الشلل الرعَّاش (مرض باركنسون) </strong>&ndash; يمكن استخدام دواء نيوبرو بمفرده أو بمصاحبة دواء آخر يُدعى ليفودوبا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ما الذي تحتاج إلى معرفته قبل استخدام دواء نيوبرو؟</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تستخدم دواء نيوبرو في الحالات الآتية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك <strong>حساسية</strong> تجاه <strong>روتيجوتين</strong> أو أي <strong>مكونات أخرى</strong> بهذا الدَّواء (المدرجة في قسم: 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بحاجة إلى الخضوع لفحص<strong> بالتَّصوير بالرنين المغناطيسي </strong>(صور تشخيصية للجسم من الدَّاخل، يتم إعدادها باستخدام الطاقة المغناطيسية فضلًا عن الأشعة السينية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بحاجة إلى &quot;<strong>تقويم نظم القلب (بالصدمة الكهربائية)</strong>&quot; (علاج مخصص لضربات القلب غير الطبيعية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك نزع لصقة دواء نيوبرو الخاصَّة بك قبل الخضوع للتصوير بالرنين المغناطيسي أو لتقويم نظم القلب (بالصدمة الكهربائية) مباشرة؛ لتجنب الإصابة بحروق جلدية إذ إنَّ اللصقة تحتوي على الألومنيوم. يمكنك وضع لصقة جديدة فيما بعد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم دواء نيوبرو إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأكدًا من ذلك، تحدَّث مع طبيبك أو الصيدلي الخاص بك أولًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك أو الممرض(ة) قبل استخدام دواء نيوبرو. وذلك بسبب الآتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي فحص <strong>ضغط الدَّم </strong>لديك بشكل منتظم أثناء استخدام دواء نيوبرو، خاصةً عند بدء العلاج. قد يُؤثر دواء نيوبرو على ضغط الدَّم لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي فحص <strong>عينيك</strong> بشكل منتظم أثناء استخدام دواء نيوبرو. إذا لاحظت أي مشاكل بالرؤية لديك أثناء الفترة ما بين الفحوصات، تحدَّث إلى طبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك <strong>مشاكل كبدية </strong>خطيرة، فقد يحتاج طبيبك إلى تغيير الجرعة. إذا تفاقمت مشاكل الكبد لديك أثناء العلاج، تحدَّث مع طبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تُصاب <strong>بمشاكل جلدية</strong> ناجمة عن اللصقة &ndash;انظر &quot;<strong>مشاكل جلدية ناجمة عن استخدام ال</strong><strong>لصقة</strong>&quot; في قسم: 4.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشعر <strong>بنعاس شديد</strong> أو <strong>قد يغلبك النعاس بشكل مفاجئ</strong> &ndash; انظر &quot;<strong>القيادة واستخدام الآلات&quot; </strong>في قسم: 2.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">اتصل بطبيبك إذا أُصبت بهذه الأعراض بعد بدء العلاج بدواء نيوبرو.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قد يحدث فقدان للوعي</strong></p><p dir="RTL">قد يتسبب دواء نيوبرو في فقدان الوعي. يحدث هذا بوجه خاص عندما تبدأ في استخدام دواء نيوبرو، أو عند زيادة جرعتك. أخبر طبيبك إذا فقدت وعيك أو شعرت بالدوخة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تغيرات في السلوك وأفكار غير سوية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يُسبب دواء نيوبرو آثارًا جانبية قد تغير من سلوكك (تصرفاتك). قد تجد أنه من المفيد إخبار أحد أفراد عائلتك أو مقدم الرعاية الخاص بك أنك تستخدم هذا الدَّواء ومطالبتهم بقراءة هذه النَّشرة. وذلك كي تستطيع عائلتك أو مقدم الرعاية الخاص بك إخبارك، أو إخبار طبيبك، ما إذا كانوا قلقين بشأن حدوث أي تغيرات في سلوكك.<br />&nbsp;</p><p dir="RTL">ويشمل ذلك الآتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; دوافع أو رغبات ملحة غير معتادة لا يمكنك مقاومتها وقد تتسبب في إيذائك أو إيذاء الآخرين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; أفكار أو سلوكيات غير سوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">انظر &quot;<strong>تغيرات في السلوك وأفكار غير سوية</strong>&quot; في قسم: 4 للمزيد من المعلومات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL"><strong>لا</strong> تعطِ هذا الدَّواء <strong>للأطفال</strong> دون 18 عامًا؛ لأنَّه من غير المعروف ما إذا كان آمنًا أو فعالًا في هذه الفئة العمرية أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام أدوية أخرى مع دواء نيوبرو</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى. بما في ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية والأدوية العشبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان يتم علاجك بدواء نيوبرو بالتَّزامن مع ليفودوبا، قد تصبح بعض الآثار الجانبية أكثر خطورة. ويشمل ذلك رؤية أو سماع أشياء لا وجود لها في الواقع (الهلاوس)، حركات لا يمكنك التَّحكم بها ذات صلة بمرض الشلل الرعَّاش (مرض باركنسون) (&quot;خلل الحركة&quot;)، وتورم الساقين والقدمين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناول الأدوية التَّالية أثناء استخدام دواء نيوبرو &ndash; فقد تحد من تأثيره:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية &quot;المضادة للذهان&quot; &ndash; تُستخدم لعلاج بعض الأمراض النفسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميتوكلوبراميد &ndash; يُستخدم لعلاج الغثيان (الشعور بالإعياء) والقيء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدَّث مع طبيبك قبل استخدام دواء نيوبرو في حال كنت تتناول الآتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المهدئة مثل: البِنزوديازيبينات أو الأدوية التي تُستخدم لعلاج الأمراض النفسية أو الاكتئاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تخفض ضغط الدَّم. قد يخفض دواء نيوبرو ضغط الدَّم عند الوقوف، وقد يتفاقم هذا التَّأثير عن طريق الأدوية المستخدمة لخفض ضغط الدَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيخبرك طبيبك ما إذا كان من الآمن الاستمرار في تناول هذه الأدوية أثناء استخدام دواء نيوبرو أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام دواء نيوبرو مع الأطعمة والمشروبات والكحوليات</strong></p><p dir="RTL">نظرًا لأنَّ روتيجوتين يدخل مجرى الدَّم لديك عبر جلدك، فلا يُؤثر تناول الأطعمة أو المشروبات على كيفية امتصاص الجسم لهذا الدَّواء. ينبغي عليك مناقشة طبيبك عما إذا كان تناوُلك للكحوليات آمنًا أثناء استخدام دواء نيوبرو أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا تستخدمي دواء نيوبرو إذا كنتِ حاملًا. وذلك لأنَّ تأثيرات روتيجوتين على الحمل والجنين غير معروفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحظر ممارسة الرضاعة الطبيعية أثناء العلاج بدواء نيوبرو. وذلك لأنَّ روتيجوتين قد يمر إلى لبن الأم ويُؤثر على طفلك. ومن المرجح أيضًا أن يخفض من كمية اللبن التي تنتجينها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي الخاص بكِ قبل استخدام هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يشعرك دواء نيوبرو بنعاس شديد وقد يغلبك النُّعاس بشكل مفاجئ. إذا حدث هذا، فلا تقم بممارسة القيادة. في حالات فردية، غلب على الأشخاص النعاس أثناء القيادة مما تسبب في وقوع حوادث.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تقم أيضًا باستخدام الأدوات أو الآلات إذا كنت تشعر بنعاس شديد &ndash; أو تقوم بشيء آخر قد يعرض الآخرين أو يعرضك لخطر حدوث إصابات خطيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي دواء نيوبرو على صوديوم ميتابيسلفيت (</strong><strong>E223</strong><strong>)</strong></p><p dir="RTL">نادرًا ما قد يتسبب صوديوم ميتابيسلفيت (E223) في الإصابة بتفاعلات فرط حساسية (حساسية) شديدة وتشنج قصبي (ضيق بالتَّنفس ناجم عن تضيق المسالك الهوائية).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيفية استخدام دواء نيوبرو</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">استخدم هذا الدَّواء بالضبط كما أخبرك طبيبك أو الصيدلي الخاص بك. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما تركيز ال</strong><strong>لصقة</strong><strong> الذي ينبغي استخدامه</strong></p><p dir="RTL">ستعتمد جرعة دواء نيوبرو على مرضك &ndash; انظر أدناه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوافر دواء نيوبرو في شكل لصقات مختلفة التركيز تعمل على إفراز الدَّواء على مدار 24 ساعة. التركيزات هي: 2 ملغ/ 24 ساعة، 4 ملغ/ 24 ساعة، 6 ملغ/ 24 ساعة و8 ملغ/ 24 ساعة لعلاج مرض الشلل الرعَّاش (مرض باركنسون).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تُضطر إلى استخدام أكثر من لصقة واحدة لبلوغ جرعتك، على النحو الذي وصفه طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; وبالنسبة للجرعات التي تفوق 8 ملغ/ 24 ساعة (الجرعات التي وصفها طبيبك والتي تفوق التركيزات المتاحة)، يجب وضع العديد من اللصقات لبلوغ الجرعة النهائية. على سبيل المثال: قد يتم بلوغ الجرعة اليومية التي تبلغ 10 ملغ/ 24 ساعة من خلال وضع لصقة واحدة 6 ملغ/ 24 ساعة ولصقة واحدة 4 ملغ/ 24 ساعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي عدم تمزيق اللصقات إلى أجزاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علاج مرض الشلل الرعَّاش (مرض باركنسون)</strong></p><p dir="RTL"><strong>المرضى ممن لا يتناولون ليفودوبا &ndash; المصابون بمرض الشلل الرعَّاش (مرض باركنسون) بالمرحلة المبكرة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستبلغ جرعة البدء اليومية الخاصَّة بك لصقة واحدة 2 ملغ/ 24 ساعة كل يوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بدءًا من الأسبوع الثَّاني قد تتم زيادة جرعتك اليومية بمقدار 2 ملغ كل أسبوع &ndash;حتى تصل إلى جرعة المداومة المناسبة لك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة لأغلبية المرضى، تتراوح الجرعة المناسبة بين 6 ملغ و8 ملغ كل يوم. وعادة ما يتم بلوغها في خلال 3 إلى 4 أسابيع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة القصوى هي 8 ملغ كل يوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرضى ممن يتناولون ليفودوبا &ndash; المصابون بمرض الشلل الرعَّاش (مرض باركنسون) بالمرحلة المتقدمة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستبلغ جرعة البدء اليومية الخاصة بك لصقة واحدة 4 ملغ/ 24 ساعة كل يوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بدءًا من الأسبوع الثاني ستتم زيادة جرعتك اليومية بمقدار 2 ملغ كل أسبوع &ndash; حتى تصل إلى جرعة المداومة المناسبة لك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة لأغلبية المرضى، تتراوح الجرعة المناسبة بين 8 ملغ و16 ملغ كل يوم. وعادة ما يتم بلوغها في خلال 3 إلى 7 أسابيع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة القصوى هي 16 ملغ كل يوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت بحاجة إلى وقف استخدام هذا الدَّواء، انظر <strong>&quot;إذا توقفت عن استخدام دواء نيوبرو&quot;</strong> في قسم: 3.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية استخدام لصقات دواء نيوبرو</strong></p><p dir="RTL">دواء نيوبرو عبارة عن لصقة يتم وضعها على الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأكد من نزعك اللصقة القديمة قبل وضع لصقة جديدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بوضع اللصقة الجديدة على <strong>منطقة مختلفة من الجلد كل يوم</strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اترك اللصقة على جلدك لمدة 24 ساعة، ثم انزعها وضع لصقة جديدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قم بتغيير اللصقات</strong> في <strong>الوقت نفسه</strong> تقريبًا <strong>من كل يوم.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تقم بتمزيق لصقات دواء نيوبرو إلى أجزاء.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:group
 id="Group_x0020_34" o:spid="_x0000_s1026" style='position:absolute;left:0;
 text-align:left;margin-left:67.6pt;margin-top:12.55pt;width:124.7pt;height:137.3pt;
 z-index:251659264' coordorigin="2723,1692" coordsize="2494,2746" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1027"
  type="#_x0000_t202" style='position:absolute;left:3568;top:1692;width:1597;
  height:413;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><b><span
     lang=AR-EG dir=RTL style='font-size:10.0pt;line-height:107%;font-family:
     "Arial","sans-serif";mso-ascii-font-family:Calibri;mso-ascii-theme-font:
     minor-latin;mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;
     mso-bidi-font-family:Arial;mso-bidi-theme-font:minor-bidi;mso-bidi-language:
     AR-EG'>أماكن وضع اللصقة</span></b><b><span style='font-size:9.0pt;
     line-height:107%'><o:p></o:p></span></b></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1028" type="#_x0000_t202"
  style='position:absolute;left:2723;top:3879;width:995;height:559;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=AR-EG dir=RTL style='font-size:9.0pt;line-height:107%;font-family:
     "Arial","sans-serif";mso-ascii-font-family:Calibri;mso-ascii-theme-font:
     minor-latin;mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;
     mso-bidi-font-family:Arial;mso-bidi-theme-font:minor-bidi;mso-bidi-language:
     AR-EG'>الجهة الأمامية</span><span style='font-size:6.0pt;line-height:107%'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1029" type="#_x0000_t202"
  style='position:absolute;left:3718;top:3879;width:705;height:559;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH
74LvEOYqbaoHEWm6B6tHFV0fYEimbdg2CZlYd9/edD8u4goeZ+b/8SOpV9tpFDNFtt4puC4rEOS0
N9b1Cj7WT8UdCE7oDI7ekYIdMayay4t6vQvEIrsdKxhSCvdSsh5oQi59IJcvnY8TpjzGXgbUG+xJ
3lTVrdTeJXKpSEsGNHVLHX6OSTxu8/pAEmlkEA8H4dKlAEMYrcaUSeXszI+W4thQZudew4MNfJUx
QP7asFzOFxx9L/lpojUkXjGmZ5wyhjSRJQ8YKGvKv1MWzIkL33VWU9lGfl98J6hz4cZ/uUjzf7Pb
bHuj+ZQu9z/UfAMAAP//AwBQSwMEFAAGAAgAAAAhADHdX2HSAAAAjwEAAAsAAABfcmVscy8ucmVs
c6SQwWrDMAyG74O9g9G9cdpDGaNOb4VeSwe7CltJTGPLWCZt376mMFhGbzvqF/o+8e/2tzCpmbJ4
jgbWTQuKomXn42Dg63xYfYCSgtHhxJEM3Elg372/7U40YalHMvokqlKiGBhLSZ9aix0poDScKNZN
zzlgqWMedEJ7wYH0pm23Ov9mQLdgqqMzkI9uA+p8T9X8hx28zSzcl8Zy0Nz33r6iasfXeKK5UjAP
VAy4LM8w09zU50C/9q7/6ZURE31X/kL8TKv1x6wXNXYPAAAA//8DAFBLAwQUAAYACAAAACEAMy8F
nkEAAAA5AAAAEAAAAGRycy9zaGFwZXhtbC54bWyysa/IzVEoSy0qzszPs1Uy1DNQUkjNS85PycxL
t1UKDXHTtVBSKC5JzEtJzMnPS7VVqkwtVrK34+UCAAAA//8DAFBLAwQUAAYACAAAACEAST0/acQA
AADbAAAADwAAAGRycy9kb3ducmV2LnhtbESP3WrCQBSE74W+w3IKvZG6sbZGo2tohZbcxvoAx+wx
CWbPhuyan7fvFgq9HGbmG2afjqYRPXWutqxguYhAEBdW11wqOH9/Pm9AOI+ssbFMCiZykB4eZntM
tB04p/7kSxEg7BJUUHnfJlK6oiKDbmFb4uBdbWfQB9mVUnc4BLhp5EsUraXBmsNChS0dKypup7tR
cM2G+dt2uHz5c5y/rj+wji92UurpcXzfgfA0+v/wXzvTClYx/H4JP0AefgAAAP//AwBQSwECLQAU
AAYACAAAACEA8PeKu/0AAADiAQAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnht
bFBLAQItABQABgAIAAAAIQAx3V9h0gAAAI8BAAALAAAAAAAAAAAAAAAAAC4BAABfcmVscy8ucmVs
c1BLAQItABQABgAIAAAAIQAzLwWeQQAAADkAAAAQAAAAAAAAAAAAAAAAACkCAABkcnMvc2hhcGV4
bWwueG1sUEsBAi0AFAAGAAgAAAAhAEk9P2nEAAAA2wAAAA8AAAAAAAAAAAAAAAAAmAIAAGRycy9k
b3ducmV2LnhtbFBLBQYAAAAABAAEAPUAAACJAwAAAAA=
" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=AR-SA dir=RTL style='font-size:9.0pt;line-height:107%;font-family:
     "Arial","sans-serif";mso-ascii-font-family:Calibri;mso-ascii-theme-font:
     minor-latin;mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;
     mso-bidi-font-family:Arial;mso-bidi-theme-font:minor-bidi'>الجهة الجانبية</span><span
     style='font-size:3.0pt;line-height:107%'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1030" type="#_x0000_t202"
  style='position:absolute;left:4512;top:3879;width:705;height:559;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=AR-SA dir=RTL style='font-size:9.0pt;line-height:107%;font-family:
     "Arial","sans-serif";mso-ascii-font-family:Calibri;mso-ascii-theme-font:
     minor-latin;mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;
     mso-bidi-font-family:Arial;mso-bidi-theme-font:minor-bidi'>الجهة الخلفية</span><span
     style='font-size:1.0pt;line-height:107%'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape></v:group><![endif]--><img width="170" height="187" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image001.png" /><strong>أين يجب وضع ال</strong><strong>لصقة</strong><strong>؟</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">ضع الجانب اللاصق من اللصقة على جلد نظيف، جاف<br />وصحي في المناطق التَّالية كما هو موضح باللون الرمادي في الصور أدناه:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكتف أو الجزء العلوي من الذراع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخصر (جانبك، بين الأضلاع والوركين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفخذ أو الورك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL"><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_33" o:spid="_x0000_i1036" type="#_x0000_t75"
   style='width:119.25pt;height:118.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image002.png"
    o:title=""/>
  </v:shape><![endif]--><img width="159" height="158" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image003.jpg" /></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>لتجنب تهيُّج الجلد</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; قم بوضع اللصقة على <strong>منطقة مختلفة من الجلد كل يوم.</strong> على سبيل المثال: ضعها على الجانب الأيمن من جسمك في يوم ثم ضعها على الجانب الأيسر من جسمك في اليوم التَّالي. أو على الجانب العلوي من جسمك في يوم ثم ضعها على الجانب السفلي من جسمك في اليوم التَّالي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تقم بإلصاق نيوبرو في ا<strong>لمنطقة نفسها من الجلد</strong> مرتين <strong>خلال 14 يومًا.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تقم بإلصاق اللصقة على <strong>جلد متضرر أو به قطع</strong> &ndash; أو على جلد به <strong>احمرار أو متهيج</strong>.</p><p dir="RTL"><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Picture_x0020_32" o:spid="_x0000_i1035" type="#_x0000_t75" style='width:104.25pt;
   height:102pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image004.png"
    o:title=""/>
  </v:shape><![endif]--><img width="139" height="136" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image005.jpg" /></p></td></tr></tbody></table><p dir="RTL">إذا كنت لا تزال تعاني من مشاكل بالجلد بسبب اللصقة، يُرجى الرجوع إلى <strong>&quot;مشاكل جلدية ناجمة عن استخدام ال</strong><strong>لصقة</strong><strong>&quot;</strong> في قسم: 4 للمزيد من المعلومات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لتجنب ارتخاء ال</strong><strong>لصقة</strong><strong> أو سقوطها</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تضع اللصقة في منطقة حيث يمكن أن <strong>تحتك بملابس ضيقة.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تستخدم أية <strong>كريمات، زيوت، غسول، مساحيق</strong> أو <strong>منتجات جلدية</strong> أخرى حيث سيتم وضع اللصقة. وكذلك لا تستخدم هذه المنتجات على اللصقة التي تضعها بالفعل أو بالقرب منها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بحاجة إلى وضع اللصقة بمنطقة مشعرة بالجلد، يجب عليك <strong>حلق الشعر</strong> من تلك المنطقة <strong>قبل</strong> وضع اللصقة <strong>بثلاثة أيام</strong> على الأقل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أزيلت أطراف اللصقة، يمكن إلصاق اللصقة باستخدام شريط طبي لاصق.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">إذا سقطت اللصقة، قم بوضع لصقة جديدة لما تبقى من اليوم &ndash; ثم استبدل اللصقة في الوقت المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لا تدع المنطقة التي تُوجد بها اللصقة تسخن &ndash;على سبيل المثال: عن طريق التَّعرض لكثير من أشعة الشمس، حمامات البخار (السونا)، الحمامات الساخنة، استخدام وسائد التَّدفئة أو زجاجات بها مياه ساخنة. هذا لأنَّ الدَّواء قد يتم إفرازه بشكل أسرع. إذا كنت تعتقد أنك تعرضت لكثير من الحرارة، اتصل بطبيبك أو الصيدلي الخاص بك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحقق دائمًا من عدم سقوط اللصقة بعد أداء الأنشطة مثل: <strong>الاستحمام، الاغتسال أو ممارسة التمارين.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تسببت اللصقة في <strong>تهيج جلدك</strong>، قم <strong>بحماية</strong> تلك المنطقة <strong>من أشعة الشمس المباشرة.</strong> هذا لأنها قد تغيُّر لون الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية استخدام ال</strong><strong>لصقة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُعبأ كل لصقة في كيس منفصل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل فتح الكيس، قم بتحديد المكان الذي ستضع فيه هذه اللصقة الجديدة وتحقق من نزعك لأي لصقة قديمة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بوضع لصقة دواء نيوبرو على جلدك بمجرد فتحك للكيس وإزالة بطانة إفراز الدَّواء.</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>1.</strong><br />لفتح الكيس، أمسك الكيس بكلا اليدين.</p></td><td style="vertical-align:top"><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Picture_x0020_31" o:spid="_x0000_i1034" type="#_x0000_t75" style='width:114pt;
   height:90pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image006.png"
    o:title=""/>
  </v:shape><![endif]--><img width="152" height="120" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image007.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>2. </strong></p><p dir="RTL">قم بإزالة الرقاقة المعدنية.</p></td><td style="vertical-align:top"><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Picture_x0020_30" o:spid="_x0000_i1033" type="#_x0000_t75" style='width:115.5pt;
   height:90.75pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image008.png"
    o:title=""/>
  </v:shape><![endif]--><img width="154" height="121" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image009.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>3.</strong><br />قم بفتح الكيس.</p></td><td style="vertical-align:top"><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Picture_x0020_29" o:spid="_x0000_i1032" type="#_x0000_t75" style='width:116.25pt;
   height:94.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image010.png"
    o:title=""/>
  </v:shape><![endif]--><img width="155" height="126" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image011.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>4.</strong><br />قم بإخراج اللصقة من الكيس.</p></td><td style="vertical-align:top"><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Picture_x0020_28" o:spid="_x0000_i1031" type="#_x0000_t75" style='width:116.25pt;
   height:87.75pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image012.png"
    o:title=""/>
  </v:shape><![endif]--><img width="155" height="117" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image013.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>5.</strong></p><p dir="RTL">الجانب اللاصق من اللصقة مغطى ببطانة إفراز شفافة.</p><p dir="RTL">&middot;&nbsp;&nbsp; أمسك اللصقة بكلا اليدين بحيث تكون بطانة الإفراز باتجاهك.</p></td><td style="vertical-align:top"><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Picture_x0020_27" o:spid="_x0000_i1030" type="#_x0000_t75" style='width:128.25pt;
   height:82.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image014.png"
    o:title=""/>
  </v:shape><![endif]--><img width="171" height="110" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image015.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>6.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بثني اللصقة من المنتصف.</p><p dir="RTL">وهذا سيعمل على ظهور الخط الفاصل الموجود بالبطانة والذي سيكون على شكل حرف &quot;إس&quot;.</p></td><td style="vertical-align:top"><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Picture_x0020_26" o:spid="_x0000_i1029" type="#_x0000_t75" style='width:115.5pt;
   height:105.75pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image016.png"
    o:title=""/>
  </v:shape><![endif]--><img width="154" height="141" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image017.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>7.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; قم بنزع جانب واحد من بطانة الإفراز.</p><p dir="RTL">&middot;&nbsp;&nbsp; لا تلمس الجانب اللاصق من اللصقة بأصابع يديك.</p></td><td style="vertical-align:top"><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Picture_x0020_25" o:spid="_x0000_i1028" type="#_x0000_t75" style='width:147.75pt;
   height:90pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image018.png"
    o:title=""/>
  </v:shape><![endif]--><img width="197" height="120" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image019.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>8.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; أمسك النصف الآخر غير اللاصق من بطانة الإفراز.</p><p dir="RTL">&middot;&nbsp;&nbsp; ثم ضع النصف اللاصق من اللصقة على جلدك.</p><p dir="RTL">&middot;&nbsp;&nbsp; اضغط على الجانب اللاصق من اللصقة بإحكام ليثبت في مكانه.</p></td><td style="vertical-align:top"><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Picture_x0020_24" o:spid="_x0000_i1027" type="#_x0000_t75" style='width:123.75pt;
   height:98.25pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image020.png"
    o:title=""/>
  </v:shape><![endif]--><img width="165" height="131" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image021.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>9.</strong><br />قم بطي النصف الآخر من اللصقة إلى الخلف وقم بنزع الجانب الآخر من بطانة الإفراز.</p></td><td style="vertical-align:top"><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Picture_x0020_23" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:123.75pt;
   height:96.75pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image022.png"
    o:title=""/>
  </v:shape><![endif]--><img width="165" height="129" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image023.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>10.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; اضغط على اللصقة لأسفل بإحكام باستخدام راحة يدك.</p><p dir="RTL">&middot;&nbsp;&nbsp; استمر في الضغط لمدة حوالي 30 ثانية.</p><p dir="RTL">هذا للتَّحقق من لمس اللصقة للجلد ومن أنَّ الأطراف قد تم لصقها بشكل جيد.</p></td><td style="vertical-align:top"><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Picture_x0020_22" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:138.75pt;
   height:92.25pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image024.png"
    o:title=""/>
  </v:shape><![endif]--><img width="185" height="123" src="file:///C:\Users\nmusa\AppData\Local\Temp\msohtmlclip1\01\clip_image025.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>11.</strong></p><p dir="RTL">اغسل يديك بالماء والصابون على الفور بعد استخدام اللصقة.</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية نزع ال</strong><strong>لصقة</strong><strong> التي تم استخدامها</strong></p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>قم بنزع اللصقة التي تم استخدامها ببطء وبحرص.</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>اغسل المنطقة برفق باستخدام الماء الدافئ والصابون الخفيف على البشرة. هذا سيزيل أي لاصق موجود على جلدك. كما يمكنك استخدام القليل من زيت الأطفال لإزالة أي لاصق لم يتم إزالته أثناء الغسل.</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>لا تستخدم الكحول أو سوائل الإذابة الأخرى &ndash;&nbsp; مثل مزيل طلاء الأظافر. فقد يُؤدي ذلك إلى تهيج جلدك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا استخدمت كمية أكثر مما يجب من دواء نيوبرو</strong></p><p dir="RTL">قد يتسبب استخدام جرعات مرتفعة من دواء نيوبرو أعلى مما وصفها لك طبيبك في حدوث آثار جانبية مثل الشعور بالإعياء (الغثيان) أو القيء، انخفاض ضغط الدَّم، رؤية أو سماع أشياء لا وجود لها في الواقع (هلاوس)، الشعور بالارتباك، نعاس شديد، التَّعرض لحركات غير إرادية وتشنجات.</p><p dir="RTL">في مثل هذه الحالات، اتصل بطبيبك أو المستشفى على الفور. سيخبرونك بما يجب القيام به.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أغفلت تغيير ال</strong><strong>لصقة</strong><strong> في موعدك المعتاد.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أغفلت تغيير اللصقة في موعدك المعتاد، قم بتغييرها بمجرد تذكرك. قم بإزالة اللصقة القديمة واستخدم لصقة جديدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أغفلت وضع لصقة جديدة بعد إزالة اللصقة القديمة، استخدم لصقة جديدة بمجرد تذكرك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في كلا الحالتين، استخدم لصقة جديدة في الموعد المعتاد في اليوم التَّالي. لا تستخدم جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام دواء نيوبرو</strong></p><p dir="RTL">لا تتوقف عن استخدام دواء نيوبرو دون التَّحدث إلى طبيبك. فقد يُؤدي التَّوقف المفاجئ إلى الإصابة بحالة طبية تُدعى &quot;المُتَلَازِمَة الخَبيثَة للدَّواءِ المُضادِّ للذُّهان&quot; والتي قد تكون مهددة للحياة. تشمل هذه العلامات: فقدان حركة العضلات (تعذر الحركة)، تصلب العضلات، حُمّى، عدم استقرار ضغط الدَّم، ارتفاع معدل ضربات القلب (تسارع ضربات القَلْب)، ارتباك، انخفاض مستوى الوعي (على سبيل المثال: غيبوبة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أوصى طبيبك بضرورة توقفك عن استخدام دواء نيوبرو، ينبغي <strong>خفض الجرعة اليومية تدريجيًّا</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مرض الشلل الرعَّاش (مرض باركنسون)</strong> &ndash;يتم خفض الجرعة بمقدار 2 ملغ مرَّة واحدة كل يومين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي الخاص بك أو الممرض(ة).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الآثار الجانبية المحتملة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع. يجب عليك إخبار طبيبك أو الصيدلي الخاص بك إذا لاحظت أية آثار جانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية التي من المرجح أن تظهر عند بدء العلاج</strong></p><p dir="RTL">قد <strong>تشعر بالإعياء</strong> (غثيان) وقد تعاني من <strong>القيء عند بداية العلاج.</strong> عادة ما تكون هذه الآثار طفيفة أو معتدلة وتدوم لفترة قصيرة فقط. <strong>تحدَّث إلى طبيبك </strong>إذا دامت لفترة طويلة أو إذا كنت قلقًا بشأنها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مشاكل جلدية ناجمة عن استخدام ال</strong><strong>لصقة</strong></p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>قد تُصاب باحمرار وحكة بالجلد حيث تم وضع اللصقة &ndash;وعادة ما تكون هذه التفاعلات طفيفة أو معتدلة.</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>تزول التفاعلات بشكل طبيعي بعد عدة ساعات &ndash;بمجرد إزالة اللصقة.</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong><strong>تحدَّث إلى طبيبك</strong> إذا كنت تعاني من تفاعل جلدي دام لأكثر من عدة أيام أو إذا كان شديدًا. وقم بذلك أيضًا إذا انتشر خارج منطقة الجلد التي كانت مغطاة باللصقة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تجنب تعريض المناطق الجلدية التي ظهر بها أي نوع من أنواع التفاعلات الجلدية النَّاجمة عن استخدام اللصقة لأشعة الشمس والحمامات الشمسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لتجنب الإصابة بتفاعلات جلدية، ينبغي عليك وضع اللصقة على منطقة مختلفة من الجلد كل يوم ولا تستخدم المنطقة نفسها مرة أخرى إِلَّا بعد مرور 14 يومًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يحدث فقدان للوعي</strong></p><p dir="RTL">قد يتسبب دواء نيوبرو في فقدان الوعي. يحدث هذا بوجه خاص عندما تبدأ في استخدام دواء نيوبرو، أو عند زيادة جرعتك. أخبر طبيبك إذا فقدت وعيك أو شعرت بالدوخة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تغيرات في السلوك وأفكار غير سوية</strong></p><p dir="RTL"><strong>أخبر طبيبك إذا لاحظت حدوث أي تغيرات في السلوك أو الأفكار أو كليهما، الواردة أدناه. فسيقوم بمناقشة طرقًا لعلاج الأعراض أو الحد منها. </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تجد أنه من المفيد أيضًا إخبار أحد أفراد عائلتك أو مقدم الرعاية الخاص بك بأنك تستخدم هذا الدَّواء ومطالبتهم بقراءة هذه النَّشرة. وذلك كي تستطيع عائلتك أو مقدم الرعاية الخاص بك إخبارك، أو إخبار طبيبك، ما إذا كانوا قلقين بشأن حدوث أي تغيرات في سلوكك. قد يتسبب دواء نيوبرو في شعورك بدوافع أو رغبات ملحة غير معتادة لا يمكنك مقاومتها مثل: وجود حافز، دافع أو استمالة للقيام بأشياء قد تتسبب في إيذائك أو إيذاء الآخرين.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">وقد يشمل ذلك ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود دافع قوي للإكثار من المقامرة &ndash;حتى وإن كان ذلك يُؤثر عليك أو على عائلتك بشكل خطير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير أو زيادة في الرَّغبة والسلوك الجنسيين مما يُسبب قلقًا بالغًا لك وللآخرين &ndash;على سبيل المثال: زيادة الرغبة الجنسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التسوق غير المتحكم به أو الإسراف في الإنفاق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشراهة (تناول كميات كبيرة من الطعام في فترة زمنية قصيرة) أو تناول الطعام القهري (تناول كمية كبيرة من الطعام أكثر من المعتاد وأكثر من الحاجة لإشباع جوعك).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتسبب دواء نيوبرو في حدوث سلوكيات أخرى وأفكار غير سوية. وقد يشمل ذلك ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اعتقادات غير سوية حول الواقع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوهام وهلاوس (رؤية أو سماع أشياء لا وجود لها في الواقع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توهان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سلوك عدواني.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هِياج.</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>هذيان.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أخبر طبيبك إذا لاحظت حدوث أي تغيرات في السلوك أو الأفكار أو كليهما، الواردة أعلاه. فسيقوم بمناقشة طرقًا لعلاج الأعراض أو الحد منها. </strong></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>تفاعلات الحساسية</strong></p><p dir="RTL">اتصل بطبيبك إذا لاحظت إصابتك بعلامات أحد تفاعلات الحساسية &ndash;وهي قد تشمل: تورم الوجه، اللسان أو الشفتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية التي قد تُصاب بها عند استخدام دواء نيوبرو لعلاج مرض الشلل الرعَّاش (مرض باركنسون)</strong></p><p dir="RTL">أخبر طبيبك، الصيدلي الخاص بك أو الممرض(ة) إذا تعرضت لأي من الآثار الجانبية التَّالية:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة جدًّا: </strong>قد تُؤثر على أكثر من 1 من بين كل 10&nbsp;أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس أو الدوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء (غثيان)، القيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور تفاعلات جلدية تحت اللصقة مثل الاحمرار والحكة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة:</strong> قد تُؤثر على ما يصل إلى 1 من بين كل 10&nbsp;أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سقوط.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فُواق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الساقين والقدمين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف (الإرهاق)، الشعور بالتَّعب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بضربات القلب (خَفَقان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك، جفاف الفَم، حموضة (حُرْقَةُ المعدة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار، زيادة التعرُّق، حكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار (الإحساس بالدوران).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية أو سماع أشياء لا وجود لها في الواقع (هلاوس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم عند النهوض، ارتفاع ضغط الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة الخلود إلى النوم، اضطراب بالنوم، صعوبة النوم، كوابيس، أحلام غير معتادة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات لا يمكنك التَّحكم بها ذات صلة بمرض الشلل الرعَّاش (مرض باركنسون) (خلل الحركة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء، الشعور بدوخة عند النهوض نظرًا لانخفاض ضغط الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على مقاومة الرَّغبة في القيام بفعل ضار، بما في ذلك الإفراط في المقامرة، والأفعال المتكررة التي لا معنى لها، التسوق غير المتحكم به أو الإسراف في الإنفاق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشراهة (تناول كمية كبيرة من الطعام في فترة زمنية قصيرة)، تناول الطعام القهري (تناول كمية كبيرة من الطعام أكثر من المعتاد وأكثر من الحاجة لإشباع الجوع).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير شائعة: </strong>قد تُؤثر على ما يصل إلى 1 من بين كل 100 شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة معدل ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الرَّغبة الجنسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب غير طبيعية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انزعاج وألم بالمعدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة معممة، تهيُّج الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوم فجأة دون سابق إنذار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العجز عن الحصول على الانتصاب أو الحفاظ عليه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بهياج، توهان، ارتباك أو ارتياب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية أو زائدة باختبارات وظائف الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالرؤية مثل: رؤية الألوان أو الأضواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات فسفوكيناز الكرياتين بالدَّم في المرضى اليابانيين (فسْفُوكيناز الكْرياتين هو إنزيم يوجد بشكل أساسي في العضلات الهيكلية)، ولا توجد معلومات متاحة في شرائح أخرى من المرضى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة: </strong>قد تُؤثر على ما يصل إلى 1 من بين كل 1000 شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوهام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بهياج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوانية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات ذهانية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي على أجزاء كبيرة من الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات عضلية غير إراداية (تشنجات).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير معروفة:</strong> من غير المعروف عدد مرات حدوث هذه الآثار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرَّغبة في استخدام جرعات كبيرة من الأدوية مثل دواء نيوبرو &ndash; أكثر من اللازم لعلاج المرض. يُعرف ذلك بـ&quot;متلازمة خلل تنظيم الدوبامين&quot; وقد يُؤدي إلى الإفراط في استخدام دواء نيوبرو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إِسْهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة تدلي الرَّأس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت أيًّا من الآثار الجانبية الواردة أعلاه، يُرجى إبلاغ طبيبك، الصيدلي الخاص بك أو الممرض(ة).</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا أُصبت بأية آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي أو الممرض(ة). ويشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرة عن طريق نظام الإبلاغ الوطني المدرج في نهاية هذه النَّشرة. من خلال إبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيفية تخزين دواء نيوبرو</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدون على الملصق والعبوة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;لا تخزن الدواء في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما يجب القيام به فيما يخص اللصقات المستخدمة وغير المستخدمة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تزال اللصقات المستخدمة تحتوي على المادة الفعَّالة &quot;روتيجوتين&quot; والتي قد تشكل ضررًا على الآخرين. قم بطي اللصقة التي تم استخدامها بحيث يكون الجانب اللاصق إلى الداخل. ضع اللصقة في الكيس الأصلي ثم قم بالتَّخلص منه بشكل آمن، بعيدًا عن مُتناوَل الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما محتويات دواء نيوبرو؟</strong></p><p dir="RTL">المادة الفعالة هي روتيجوتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 ملغ/ 24 ساعة:</p><p dir="RTL">تفرز كل لصقة 2 ملغ من روتيجوتين كل 24 ساعة. تحتوي كل لصقة مساحتها 10 سنتيمتر مربع على 4.5 ملغ من روتيجوتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 ملغ/ 24 ساعة:</p><p dir="RTL">تفرز كل لصقة 4 ملغ من روتيجوتين كل 24 ساعة. تحتوي كل لصقة مساحتها 20 سنتيمتر مربع على 9.0 ملغ من روتيجوتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6 ملغ/ 24 ساعة:</p><p dir="RTL">تفرز كل لصقة 6 ملغ من روتيجوتين كل 24 ساعة. تحتوي كل لصقة مساحتها 30 سنتيمتر مربع على 13.5 ملغ من روتيجوتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8 ملغ/ 24 ساعة:</p><p dir="RTL">تفرز كل لصقة 8 ملغ من روتيجوتين كل 24 ساعة. تحتوي كل لصقة مساحتها 40 سنتيمتر مربع على 18.0 ملغ من روتيجوتين.</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عديد (ثنائي ميثيل السيلوكسان وسيليكات ثلاثي ميثيل السيليل) -البوليمر المشترك ، و بوفيدون K90، وميتابيسلفيت الصوديوم (E223)، وبالميتات الأسكوربيل (E304) و دي إل-ألفا-توكوفيرول (E307).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طبقة التغليف: غلاف من البوليستر، معالجة بالسيليكون والألمونيوم ومطلي بطبقة من الصبغة (ثاني أكسيد التيتانيوم (E171)، وصبغة صفراء 95، وصبغة حمراء 166) ومنقوش عليه (صبغة حمراء 144، وصبغة صفراء 95، وصبغة سوداء 7).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطانة الإفراز: غلاف من البوليستر مغطى ببوليمر فلوريني شفاف.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما شكل دواء نيوبرو؟ وما محتويات العبوة؟</strong></p><p dir="RTL">دواء نيوبرو عبارة عن لصقة جلدية. وهي لصقة رقيقة وبها ثلاث طبقات. تكون على شكل مربع وذات حواف دائرية. السطح الخارجي يكون برتقالي اللون ومنقوش عليه نيوبرو 2 ملغ/ 24 ساعة، نيوبرو 4 ملغ/ 24 ساعة، نيوبرو 6 ملغ/ 24 ساعة أو نيوبرو 8 ملغ/ 24 ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوافر دواء نيوبرو في عبوات بالأحجام التَّالية:</p><p dir="RTL">عبوات بها 7 أو 28 لصقة، كل منها مغلف بشكل فردى داخل كيس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>جهة التصنيع </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">LTS Lohmann Therapie-Systeme AG,</p><p dir="RTL">Lohmannstrase 2, D-56626 Andernach, Germany</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>Batch Release Site</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">UCB Pharma S.A.</p><p dir="RTL">Chemin du Foriest</p><p dir="RTL">B-1420 Braine l&rsquo;Alleud</p><p dir="RTL">Belgium</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مالك حق التفويض بالتسويق </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">UCB Pharma S.A.</p><p dir="RTL">All&eacute;e de la Recherche 60</p><p dir="RTL">B-1070 Bruxelles</p><p dir="RTL">Belgium</p><p dir="RTL">&nbsp;</p><p>لمزيد من المعلومات حول هذا الدواء، الرجاء الاتصال بالممثل المحلي لمالك حق التفويض بالتسويق</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             {2018/6}
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Neupro 4 mg/24 h transdermal patch 
Neupro 6 mg/24 h transdermal patch 
Neupro 8 mg/24 h transdermal patch
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Neupro 4 mg/24 h transdermal patch
Each patch releases 4 mg of rotigotine per 24 hours. Each patch of 20 cm2 contains 9.0 mg of rotigotine.

Neupro 6 mg/24 h transdermal patch
Each patch releases 6 mg of rotigotine per 24 hours. Each patch of 30 cm2 contains 13.5 mg of rotigotine.

Neupro 8 mg/24 h transdermal patch
Each patch releases 8 mg of rotigotine per 24 hours. Each patch of 40 cm2 contains 18.0 mg of rotigotine.

For the full list of excipients, see section 6.1.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Transdermal patch.
Thin, matrix-type, square-shaped with rounded edges, consisting of three layers.

Neupro 4 mg/24 h transdermal patch
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 4 mg/24 h’.

Neupro 6 mg/24 h transdermal patch
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 6 mg/24 h’.

Neupro 8 mg/24 h transdermal patch
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 8 mg/24 h’.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.1&nbsp;&nbsp;&nbsp; Therapeutic indications</strong></p><p>&nbsp;</p><p>Neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson&rsquo;s disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or &lsquo;on-off&rsquo; fluctuations).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.2&nbsp;&nbsp;&nbsp; Posology and method of administration</strong></p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The dose recommendations made are in nominal dose.</p><p>&nbsp;</p><p><em>Dosing in patients with early-stage Parkinson&rsquo;s disease:</em></p><p>&nbsp;</p><p>A single daily dose should be initiated at 2 mg/24 h and then increased in weekly increments of</p><p>2 mg/24 h to an effective dose up to a maximum dose of 8 mg/24 h.</p><p>4 mg/24 h may be an effective dose in some patients. For most patients an effective dose is reached within 3 or 4 weeks at doses of 6 mg/24 h or 8 mg/24 h, respectively.</p><p>The maximum dose is 8 mg/24 h.</p><p>&nbsp;</p><p><em>Dosing in patients with advanced stage Parkinson&rsquo;s disease with fluctuations:</em></p><p>A single daily dose should be initiated at 4 mg/24 h and then increased in weekly increments of</p><p>2 mg/24 h to an effective dose up to a maximum dose of 16 mg/24 h.</p><p>4 mg/24 h or 6 mg/24 h may be effective doses in some patients. For most patients an effective dose is reached within 3 to 7 weeks at doses of 8 mg/24 h up to a maximum dose of 16 mg/24 h.</p><p>&nbsp;</p><p>For doses higher than 8 mg/24 h multiple patches may be used to achieve the final dose e.g.</p><p>10 mg/24 h may be reached by combination of a 6 mg/24 h and a 4 mg/24 h patch.</p><p>&nbsp;</p><p>Neupro is applied once a day. The patch should be applied at approximately the same time every day. The patch remains on the skin for 24 hours and will then be replaced by a new one at a different site of application.</p><p>&nbsp;</p><p>If the patient forgets to apply the patch at the usual time of the day or if the patch becomes detached, another patch should be applied for the remainder of the day.</p><p>&nbsp;</p><p><em>Treatment discontinuation</em></p><p>&nbsp;</p><p>Neupro should be discontinued gradually. The daily dose should be reduced in steps of 2 mg/24 h with a dose reduction preferably every other day, until complete withdrawal of Neupro (see section 4.4).</p><p>&nbsp;</p><p><u>Special &nbsp;populations</u></p><p>&nbsp;</p><p><em>H</em><em>epatic impairment</em></p><p>&nbsp;</p><p>Adjustment of the dose is not necessary in patients with mild to moderate hepatic impairment. Caution is advised when treating patients with severe hepatic impairment, which may result in lower rotigotine clearance. Rotigotine has not been investigated in this patient group. A dose reduction might be needed in case of worsening of the hepatic impairment.</p><p>&nbsp;</p><p><em>R</em><em>enal impairment</em></p><p>&nbsp;</p><p>Adjustment of the dose is not necessary in patients with mild to severe renal impairment, including those requiring dialysis. Unexpected accumulation of rotigotine levels may also occur at acute worsening of renal function (see section 5.2).</p><p>&nbsp;</p><p><em>P</em><em>aediatric population</em></p><p>There is no relevant use of Neupro in the paediatric population in Parkinson&rsquo;s disease. <u>Method of administration</u></p><p>&nbsp;</p><p>Neupro is for transdermal use.</p><p>&nbsp;</p><p>The patch should be applied to clean, dry, intact healthy skin on the abdomen, thigh, hip, flank, shoulder, or upper arm. Reapplication to the same site within 14 days should be avoided. Neupro should not be placed on skin that is red, irritated or damaged (see section 4.4).</p><p>&nbsp;</p><p><em>Use and handling</em></p><p>&nbsp;</p><p>Each patch is packed in a sachet and should be applied directly after the sachet has been opened. One half of the release liner should be removed and the sticky side should be applied and pressed firmly to the skin. Then, the patch is fold back and the second part of the release liner is removed. The sticky side of the patch should not be touched. The patch should be pressed down firmly with the palm of the hand for about 30 seconds, so that it sticks well.</p><p>&nbsp;</p><p>The patch should not be cut into pieces.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4.3	Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Magnetic resonance imaging or cardioversion (see section 4.4).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.4&nbsp;&nbsp;&nbsp; Special warnings and precautions for use</strong></p><p>&nbsp;</p><p>If a Parkinson&rsquo;s disease patient is insufficiently controlled while on treatment with rotigotine switching to another dopamine agonist might provide additional benefit (see section 5.1)</p><p>&nbsp;</p><p><u>Magnetic resonance imaging and cardioversion</u></p><p>&nbsp;</p><p>The backing layer of Neupro contains aluminium. To avoid skin burns, Neupro should be removed if the patient has to undergo magnetic resonance imaging (MRI) or cardioversion.</p><p>&nbsp;</p><p><u>Orthostatic &nbsp;hypotension</u></p><p>&nbsp;</p><p>Dopamine agonists are known to impair the systemic regulation of the blood pressure resulting in postural/orthostatic hypotension. These events have also been observed during treatment with rotigotine, but the incidence was similar to that observed in placebo-treated patients.</p><p>It is recommended to monitor blood pressure, especially at the beginning of treatment, due to the general risk of orthostatic hypotension associated with dopaminergic therapy.</p><p>&nbsp;</p><p><u>Syncope</u></p><p>&nbsp;</p><p>In clinical studies with rotigotine, syncope has been observed at a rate that was similar to that observed in patients treated with placebo. Because patients with clinically relevant cardiovascular disease were excluded in these studies, patients with severe cardiovascular disease should be asked about symptoms of syncope and pre-syncope.</p><p>&nbsp;</p><p><u>Sudden onset of sleep and somnolence</u></p><p>&nbsp;</p><p>Rotigotine has been associated with somnolence and episodes of sudden sleep onset. Sudden onset of sleep during daily activities, in some cases without awareness of any warning signs, has been</p><p>reported. Prescribers should continually reassess patients for drowsiness or sleepiness, as patients may not acknowledge drowsiness or sleepiness until directly questioned. A reduction of dosage or termination of therapy should be carefully considered.</p><p>&nbsp;</p><p><u>Impulse control disorders</u></p><p>&nbsp;</p><p>Patients should be regularly monitored for the development of impulse control disorders. Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathologic gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists, including rotigotine. Dose reduction/tapered discontinuation should be considered if such symptoms develop.</p><p>&nbsp;</p><p><u>Neuroleptic malignant syndrome</u></p><p>&nbsp;</p><p>Symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy. Therefore, it is recommended to taper treatment (see section 4.2).</p><p>&nbsp;</p><p><u>Abnormal thinking and behavior</u></p><p>&nbsp;</p><p>Abnormal thinking and behaviour have been reported and can consist of a variety of manifestations including paranoid ideation, delusions, hallucinations, confusion, psychotic-like behaviour, disorientation, aggressive behaviour, agitation, and delirium.</p><p>&nbsp;</p><p><u>Fibrotic complications</u></p><p>&nbsp;</p><p>Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, pericarditis and cardiac valvulopathy have been reported in some patients treated with ergot-derived dopaminergic agents. While these complications may resolve when treatment is discontinued, complete resolution does not always occur.</p><p>Although these adverse reactions are believed to be related to the ergoline structure of these compounds, whether other, nonergot derived dopamine agonists can cause them is unknown.</p><p>&nbsp;</p><p><u>Neuroleptics</u></p><p>&nbsp;</p><p>Neuroleptics given as antiemetic should not be given to patients taking dopamine agonists (see also section 4.5).</p><p>&nbsp;</p><p><u>Ophthalmologic &nbsp;monitoring</u></p><p>&nbsp;</p><p>Ophthalmologic monitoring is recommended at regular intervals or if vision abnormalities occur.</p><p>&nbsp;</p><p><u>Heat application</u></p><p>&nbsp;</p><p>External heat (excessive sunlight, heating pads and other sources of heat such as sauna, hot bath)</p><p>should not be applied to the area of the patch.</p><p>&nbsp;</p><p><u>Application &nbsp;site reactions</u></p><p>&nbsp;</p><p>Application site skin reactions may occur and are usually mild or moderate in intensity. It is recommended that the application site should be rotated on a daily basis (e.g. from the right side to the left side and from the upper body to the lower body). The same site should not be used within</p><p>14 days. If application site reactions occur which last for more than a few days or are persistent, if there is an increase in severity, or if the skin reaction spreads outside the application site, an assessment of the risk/benefit balance for the individual patient should be conducted.</p><p>If there is a skin rash or irritation from the transdermal system, direct sunlight on the area should be avoided until the skin heals, as exposure could lead to changes in the skin color.</p><p>If a generalised skin reaction (e.g. allergic rash, including erythematous, macular, papular rash or pruritus) associated with the use of Neupro is observed, Neupro should be discontinued.</p><p>&nbsp;</p><p><u>Peripheral &nbsp; oedema</u></p><p>&nbsp;</p><p>In clinical studies in Parkinson&rsquo;s patients, the 6 month-specific rates of peripheral oedema remained at about 4% through the entire observation period up to 36 months.</p><p>&nbsp;</p><p><u>Dopaminergic adverse reactions</u></p><p>&nbsp;</p><p>The incidence of some dopaminergic adverse reactions, such as hallucinations, dyskinesia, and peripheral oedema generally is higher when given in combination with L-dopa in Parkinson&rsquo;s patients. This should be considered when prescribing rotigotine.</p><p>&nbsp;</p><p><u>Sulphite &nbsp;sensitivity</u></p><p>&nbsp;</p><p>Neupro contains sodium metabisulphite, a sulphite that may cause allergic-type reactions including anaphylactic symptoms and life threatening or less severe asthmatic episodes in certain susceptible people.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.5&nbsp;&nbsp;&nbsp; Interaction with other medicinal products and other forms of interaction</strong></p><p>&nbsp;</p><p>Because rotigotine is a dopamine agonist, it is assumed that dopamine antagonists, such as neuroleptics (e.g. phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of Neupro, and co-administration should be avoided. Because of possible additive effects, caution should be advised when patients are taking sedating medicinal products or other CNS (central nervous system) depressants (e.g. benzodiazepines, antipsychotics, antidepressants) or alcohol in combination with rotigotine.</p><p>&nbsp;</p><p>Co-administration of L-dopa and carbidopa with rotigotine had no effect on the pharmacokinetics of rotigotine, and rotigotine had no effect on the pharmacokinetics of L-dopa and carbidopa.</p><p>Co-administration of domperidone with rotigotine had no effect on the pharmacokinetics of rotigotine. Co-administration of omeprazole (inhibitor of CYP2C19), in doses of 40 mg/day, had no effect on the</p><p>pharmacokinetics and metabolism of rotigotine in healthy volunteers.</p><p>&nbsp;</p><p>Neupro may potentiate the dopaminergic adverse reaction of L-dopa and may cause and/or exacerbate pre-existing dyskinesia, as described with other dopamine agonists.</p><p>&nbsp;</p><p>Co-administration of rotigotine (3 mg/24 h) did not affect the pharmacodynamics and pharmacokinetics of oral contraceptives (0.03 mg ethinylestradiol, 0.15 mg levonorgestrel). Interactions with other forms of hormonal contraception have not been investigated.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.6&nbsp;&nbsp;&nbsp; Fertility, pregnancy and lactation</strong></p><p>&nbsp;</p><p><u>Women of childbearing potential, contraception in females</u></p><p>&nbsp;</p><p>Women of childbearing potential should use effective contraception to prevent pregnancy during treatment with rotigotine.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no adequate data from the use of rotigotine in pregnant women. Animal studies do not indicate any teratogenic effects in rats and rabbits, but embryo-toxicity was observed in rats and mice at materno-toxic doses (see section 5.3). The potential risk for humans is unknown. Rotigotine should not be used during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>Because rotigotine decreases prolactin secretion in humans, inhibition of lactation is expected. Studies in rats have shown that rotigotine and/or its metabolite(s) are excreted in breast milk. In the absence</p><p>of human data, breast-feeding should be discontinued.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>For information on fertility studies, please see section 5.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to drive and use machines</strong></p><p>&nbsp;</p><p>Rotigotine may have major influence on the ability to drive and use machines.</p><p>Patients being treated with rotigotine and presenting with somnolence and/or sudden sleep episodes must be informed not to drive or engage in activities (e.g. operating machines) where impaired alertness may put themselves or others at risk of serious injury or death until such recurrent episodes and somnolence have resolved (see also sections 4.4 and 4.5).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable effects</strong></p><p>&nbsp;</p><p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>Based on the analysis of pooled placebo-controlled clinical trials comprising a total of 1,307 Neupro- and 607 placebo-treated patients, 72.5% of the patients on Neupro and 58.0% of patients on placebo reported at least one adverse reaction.</p><p>&nbsp;</p><p>At the beginning of therapy dopaminergic adverse reactions such as nausea and vomiting may occur. These are usually mild or moderate in intensity and transient even if treatment is continued.</p><p>&nbsp;</p><p>Adverse drug reactions (ADRs) reported in more than 10% of patients treated with Neupro transdermal patch are nausea, vomiting, application site reactions, somnolence, dizziness and headache.</p><p>&nbsp;</p><p>In trials where the application sites were rotated as reflected in the instructions provided in SmPC and package leaflet, 35.7% of 830 patients using the Neupro transdermal patch, experienced application site reactions. The majority of application site reactions were mild or moderate in intensity, limited to the application areas and resulted in discontinuation of treatment with Neupro in only 4.3% of all subjects receiving Neupro.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The following table covers adverse drug reactions from the pooled studies mentioned above in patients with Parkinson&rsquo;s disease and from post-marketing experience. Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System/organ classes acc. to MedDRA</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity, which may include angioedema, tongue oedema and lip oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Psychiatric </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Perception disturbancesa (incl. hallucination, hallucination visual, hallucination auditory, illusion), insomnia, sleep disorder, nightmare, abnormal</p><p>dreams, impulse- control disordersa,d (incl. pathological gambling, stereotypy/ punding, binge eating/eating disorderb, compulsive shoppingc)</p></td><td style="vertical-align:top"><p>Sleep attacks/sudden onset of sleep, paranoia, sexual desire disordersa (incl. hypersexuality, libido increased), confusional</p><p>state, disorientationd, agitationd</p></td><td style="vertical-align:top"><p>Psychotic disorder, obsessive- compulsive disorder, aggressive behaviour/ aggressionb, delusiond, deliriumd</p></td><td style="vertical-align:top"><p>Dopamine dysregulation syndromec</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Somnolence, dizziness, headache</p></td><td style="vertical-align:top"><p>Disturbances in consciousness NECa (incl. syncope, syncope vasovagal, loss of consciousness), dyskinesia, dizziness postural, lethargy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Convulsion</p></td><td style="vertical-align:top"><p>Dropped head syndrome<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vision blurred, visual impairment, photopsia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Atrial fibrillation</p></td><td style="vertical-align:top"><p>Supraventricular tachycardia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Orthostatic hypotension, hypertension</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hiccups</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Nausea, vomiting</p></td><td style="vertical-align:top"><p>Constipation, dry mouth,</p><p>dyspepsia</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Diarrhoea<sup>c</sup></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erythema, hyperhidrosis, pruritus</p></td><td style="vertical-align:top"><p>Pruritus generalised, skin irritation, dermatitis contact</p></td><td style="vertical-align:top"><p>Rash generalised</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorder</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Application and instillation site reactionsa (incl. erythema, pruritus, irritation, rash, dermatitis, vesicles, pain, eczema, inflammation, swelling, discolouration, papules, exfoliation, urticaria, hypersensitivity)</p></td><td style="vertical-align:top"><p>Oedema peripheral, asthenic conditionsa (incl. fatigue, asthenia, malaise)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Irritability</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:top"><p>Hepatic enzyme increased (incl. AST, ALT, GGT), weight increased, heart rate increased, CPK increasedd (see Special populations)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fall</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>a High Level Term</p><p>b Observed in open-label studies</p><p>c Observed during post-marketing</p><p>d Observed in 2011 data pool of double-blind placebo-controlled studies</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Sudden onset of sleep and somnolence</em></p><p>&nbsp;</p><p>Rotigotine has been associated with somnolence including excessive daytime somnolence and sudden sleep onset episodes. In isolated cases &ldquo;sudden onset of sleep&rdquo; occurred while driving and resulted in motor vehicle accidents (see also sections 4.4 and 4.7).</p><p>&nbsp;</p><p><em>Impulse control disorders</em></p><p>&nbsp;</p><p>Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists, including rotigotine (see section 4.4).</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p>Adverse reactions of increased creatine phosphokinase (CPK) were observed with rotigotine in clinical studies conducted in Japan. These occurred in 3.4% of Japanese subjects on rotigotine compared to 1.9% on placebo in double-blind Parkinson&rsquo;s disease. The majority of the adverse reactions of increased CPK observed in all double-blind and open-label studies resolved and were considered mild in severity. CPK levels have not been routinely measured in other populations.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed below:</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp; &nbsp;<strong>Saudi Arabia:</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>-&nbsp; &nbsp;The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; &nbsp;<strong>Other GCC States:</strong></p><p>&nbsp;</p><p>-&nbsp; &nbsp;Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.9&nbsp;&nbsp;&nbsp; Overdose</strong></p><p>&nbsp;</p><p><u>Symptoms</u></p><p>&nbsp;</p><p>The most likely adverse reactions would be those related to the pharmacodynamic profile of a dopamine agonist, including nausea, vomiting, hypotension, involuntary movements, hallucinations, confusion, convulsions and other signs of central dopaminergic stimulation.</p><p>&nbsp;</p><p><u>Management</u></p><p>&nbsp;</p><p>There is no known antidote for overdose of dopamine agonists. In case of suspected overdose, removal of the patch(es) should be considered because after removal of the patch(es) the active substance input is stopped and the plasma concentration of rotigotine decreases rapidly. The patient should be monitored closely, including heart rate, heart rhythm and blood pressure.</p><p>Treatment of overdose may require general supportive measures to maintain the vital signs. Dialysis would not be expected to be beneficial as rotigotine is not eliminated by dialysis.</p><p>&nbsp;</p><p>If it is necessary to discontinue rotigotine, this should be done gradually to prevent neuroleptic malignant syndrome.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1&nbsp;&nbsp;&nbsp; Pharmacodynamic properties</strong></p><p>&nbsp;</p><p>Pharmacotherapeutic group: Anti-parkinson drugs, dopamine agonists; ATC code: N04BC09</p><p>&nbsp;</p><p>Rotigotine is a non-ergolinic dopamine agonist for the treatment of signs and symptoms of</p><p>Parkinson&rsquo;s disease</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Rotigotine is believed to elicit its beneficial effect on Parkinson&rsquo;s disease by activation of the D3, D2</p><p>and D1 receptors of the caudate-putamen in the brain.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p>Regarding the functional activity at the various receptor subtypes and their distribution in the brain, rotigotine is a D2 and D3 receptor agonist acting also on D1, D4 and D5 receptors. With non- dopaminergic receptors, rotigotine showed antagonism at alpha2B and agonism at 5HT1A receptors, but no activity on the 5HT2B receptor.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>The effectiveness of rotigotine in the treatment of the signs and symptoms of idiopathic Parkinson&#39;s disease was evaluated in a multinational drug development program consisting of four pivotal, parallel, randomized, double-blind placebo controlled studies and three studies investigating specific aspects of Parkinson&rsquo;s disease.</p><p>&nbsp;</p><p><strong>Tw</strong><strong>o pivotal trials (SP512 Part I and SP513 Part I) </strong>investigating the effectiveness of rotigotine in the treatment of the signs and symptoms of idiopathic Parkinson&rsquo;s disease were conducted in patients who were not receiving concomitant dopamine agonist therapy and were either L-dopa na&iuml;ve or previous L-dopa treatment was &le; 6 months. The primary outcome assessment was the score for the Activities of Daily Living (ADL) component (Part II) plus the Motor Examination component (Part III) of the Unified Parkinson&rsquo;s Disease Rating Scale (UPDRS).</p><p>Efficacy was determined by the subject&rsquo;s response to therapy in terms of responder and absolute points improvement in the scores of ADL and Motor Examination combined (UPDRS part II+III).</p><p>&nbsp;</p><p><strong>In the double blind study SP512 Part I</strong>, 177 patients received rotigotine and 96 patients received placebo. The patients were titrated to their optimal dose of rotigotine or placebo in weekly increments of 2 mg/24 h starting at 2 mg/24 h to a maximum dose of 6 mg/24 h. Patients in each treatment group were maintained at their optimal dose for 6 months.</p><p>At the end of the maintenance treatment in 91% of the subjects in the rotigotine arm, the optimal dose was the maximal dose allowed i.e. 6 mg/24 h. An improvement of 20% was seen in 48% of the subjects receiving rotigotine and in 19% of the subjects receiving placebo (Difference 29%, CI95%</p><p>18%; 39%, p&lt;0.0001). With rotigotine, the mean improvement in the UPDRS score (Parts II + III)</p><p>was -3.98 points (baseline 29.9 points) whereas in the placebo-treated arm a worsening of 1.31 points was observed (baseline 30.0 points). The difference was 5.28 points and statistically significant (p&lt;0.0001).</p><p>&nbsp;</p><p><strong>In the double-blind study SP513 Part I</strong>, 213 patients received rotigotine, 227 received ropinirole and 117 patients received placebo. The patients were titrated to their optimal dose of rotigotine in weekly increments of 2 mg/24 h starting at 2 mg/24 h to a maximum dose of 8 mg/24 h over 4 weeks. In the ropinirole group, patients were titrated to their optimal dose up to a maximum of 24 mg/day over 13 weeks. Patients in each treatment group were maintained for 6 months.</p><p>At the end of the maintenance treatment in 92% of the subjects in the rotigotine arm, the optimal dose was the maximal dose allowed i.e. 8 mg/24 h. An improvement of 20% was seen in 52% of the subjects receiving rotigotine, 68% of the subjects receiving ropinirole and 30% of the subjects receiving placebo (Difference rotigotine <em>versus </em>placebo 21.7%, CI95% 11.1%; 32.4%, difference ropinirole <em>versus </em>placebo 38.4%, CI95% 28.1%; 48.6%, difference ropinirole <em>versus </em>rotigotine 16.6%, CI95% 7.6%; 25.7%). The mean improvement in the UPDRS score (Parts II + III) was 6.83 points (baseline 33.2 points) in the rotigotine arm, 10.78 points in the ropinirole arm (baseline 32.2 points) and 2.33 points in the placebo arm (baseline 31.3 points). All differences between the active treatments and placebo were statistically significant. This study failed to demonstrate non-inferiority of rotigotine to ropinirole.</p><p>&nbsp;</p><p><strong>In a subsequent open-label study (SP824)</strong>, a multicenter, multinational study, the tolerability of overnight switching from ropinirole, pramipexole or cabergoline to rotigotine transdermal patch and its effect on symptoms in subjects with idiopathic Parkinson&rsquo;s disease have been studied. 116 patients were switched from previous oral therapy to receive up to 8 mg/24 h of rotigotine, among these were</p><p>47 who had been treated with ropinirole up to 9 mg/day, 47 who had been treated with pramipexole up to 2 mg/day and 22 who had been treated with cabergoline up to 3 mg/day. Switching to rotigotine was feasible, with minor dose adjustment (median 2 mg/24 h) being necessary in only 2 patients switching from ropinirole, 5 patients from pramipexole and 4 patients from cabergoline. Improvements were seen in UPDRS Parts I - IV scores. The safety profile was unchanged from that observed in previous studies.</p><p>&nbsp;</p><p><strong>In a randomized, open-label study (SP825) </strong>in patients with early stage Parkinson&rsquo;s disease, 25 patients were randomized to rotigotine treatment and 26 to ropinirole. In both arms treatment was titrated to optimal or maximum dose of 8 mg/24 h or 9 mg/day, respectively. Both treatments showed improvements in early morning motor function and sleep. Motor symptoms (UPDRS Part III) improved by 6.3 &plusmn; 1.3 points in rotigotine-treated patients, and by 5.9 &plusmn; 1.3 points in the ropinirole- group after 4 weeks of maintenance. Sleep (PDSS) improved by 4.1 &plusmn; 13.8 points for rotigotine- treated patients, and by 2.5 &plusmn; 13.5 points for ropinirole-treated patients. The safety profile was comparable, with the exception of application site reactions.</p><p>&nbsp;</p><p>In studies SP824 and SP825 conducted since the initial comparative trial, rotigotine and ropinirole at equivalent doses were shown to have comparable efficacy.</p><p>&nbsp;</p><p><strong>Two additional pivotal trials (SP650DB and SP515) </strong>were conducted in patients who were receiving concomitant levodopa therapy. The primary outcome assessment was the reduction in &ldquo;off&rdquo; time (hours). Efficacy was determined by the subject&rsquo;s response to therapy in terms of responder and absolute improvement in the time spent &ldquo;off&rdquo;.</p><p>&nbsp;</p><p><strong>In the double blind study SP650DB</strong>, 113 patients received rotigotine up to a maximum dose of</p><p>8 mg/24 h, 109 patients received rotigotine up to a maximum dose of 12 mg/24 h and 119 patients received placebo. The patients were titrated to their optimal doses of rotigotine or placebo in weekly increments of 2 mg/24 h starting at 4 mg/24 h. Patients in each treatment group were maintained at their optimal dose for 6 months. At the end of the maintenance treatment an improvement of at least</p><p>30% was seen in 57% and 55% of the subjects receiving rotigotine 8 mg/24 h and 12 mg/24 h, respectively and in 34% of the subjects receiving placebo (Differences 22% and 21%, respectively, CI95% 10%; 35% and 8%; 33%, respectively, p&lt;0.001 for both rotigotine groups). With rotigotine, the mean reductions in &ldquo;off&rdquo; time were 2.7 and 2.1 hours, respectively whereas in the placebo-treated arm a reduction of 0.9 hours was observed. The differences were statistically significant (p&lt;0.001 and p=0.003, respectively).</p><p>&nbsp;</p><p><strong>In the double-blind study SP515</strong>, 201 patients received rotigotine, 200 received pramipexole and</p><p>100 patients received placebo. The patients were titrated to their optimal dose of rotigotine in weekly increments of 2 mg/24 h starting at 4 mg/24 h to a maximum dose of 16 mg/24 h. In the pramipexole group, patients received 0,375 mg in the first week, 0.75 mg in the second week and were titrated further in weekly increments of 0.75 mg to their optimal dose up to a maximum of 4.5 mg/day. Patients in each treatment group were maintained for 4 months.</p><p>At the end of the maintenance treatment an improvement of at least 30% was seen in 60% of the subjects receiving rotigotine, 67% of the subjects receiving pramipexole and 35% of the subjects receiving placebo (Difference rotigotine <em>versus </em>placebo 25%, CI95% 13%; 36%, difference pramipexole <em>versus </em>placebo 32%, CI95% 21%; 43%, difference pramipexole <em>versus </em>rotigotine 7%, CI95% -2%; 17%). The mean reduction in the &ldquo;off&rdquo; time was 2.5 hours in the rotigotine arm, 2.8 hours in the pramipexole arm and 0.9 hours in the placebo arm. All differences between the active treatments and placebo were statistically significant.</p><p>&nbsp;</p><p><strong>A further multinational double-blind study (SP889) </strong>was conducted in 287 patients with early or advanced stages of Parkinson&rsquo;s disease who had unsatisfactory early morning motor symptom control.</p><p>81.5% of these patients were on concomitant levodopa therapy. 190 patients received rotigotine, and</p><p>97 placebo. The patients were titrated to their optimal dose of rotigotine or placebo in weekly increments of 2 mg/24 h starting at 2 mg/24 h to a maximum dose of 16 mg/24 h over 8 weeks, followed by a maintenance period of 4 weeks. Early morning motor function, assessed by UPDRS part III, and nocturnal sleep disturbances, measured by the modified Parkinson&rsquo;s Disease Sleep Scale (PDSS-2), were co-primary outcome measures. At the end of maintenance, the mean UPDRS part III</p><p>score had improved by 7.0 points in rotigotine-treated patients (baseline 29.6), and by 3.9 points in the placebo-group (baseline 32.0). Improvements in the mean PDSS-2 total score were 5.9 (rotigotine, baseline 19.3) and 1.9 points (placebo, baseline 20.5). Treatment differences for the coprimary variables were statistically significant (p=0.0002 and p&lt;0.0001).</p><p>&nbsp;</p><p><em>Skin adhesion</em></p><p>&nbsp;</p><p>In a multicenter, double-blind, randomized, 2-way, crossover study in 52 outpatients, the skin adhesion of the improved room temperature patch formulation was compared to the cold storage formulation, using the 8 mg/24 h rotigotine patch. Skin adhesion was measured on 2 consecutive days of 24 hours patch application. The improved room temperature patch formulation showed better skin adhesion than the cold storage formulation with &gt;90% of patches showing sufficient adhesion (i.e.</p><p>&gt;70% of the patch area adhering) compared to &lt;83%. Comparable skin tolerability was reported for both formulations. The majority of erythema observed was mild and none severe.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.2&nbsp;&nbsp;&nbsp; Pharmacokinetic properties</strong></p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>Following application, rotigotine is continuously released from the transdermal patch and absorbed through the skin. Steady-state concentrations are reached after one to two days of patch application and are maintained at a stable level by once daily application in which the patch is worn for 24 hours. Rotigotine plasma concentrations increase dose-proportionally over a dose range of 1 mg/24 h to</p><p>24 mg/24 h.</p><p>&nbsp;</p><p>Approximately 45% of the active substance within the patch is released to the skin in 24 hours. The absolute bioavailability after transdermal application is approximately 37%.</p><p>&nbsp;</p><p>Rotating the site of patch application may result in day-to-day differences in plasma levels.</p><p>Differences in bioavailability of rotigotine ranged from 2% (upper arm <em>versus </em>flank) to 46% (shoulder</p><p><em>versus </em>thigh). However, there is no indication of a relevant impact on the clinical outcome.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The <em>i</em><em>n vitro </em>binding of rotigotine to plasma proteins is approximately 92%. The apparent volume of distribution in humans is approximately 84 l/kg.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Rotigotine is metabolised to a great extent. Rotigotine is metabolised by N-dealkylation as well as direct and secondary conjugation. <em>In vitro </em>results indicate that different CYP isoforms are able to catalyse the N-dealkylation of rotigotine. Main metabolites are sulfates and glucuronide conjugates of the parent compound as well as N-desalkyl-metabolites, which are biologically inactive.</p><p>The information on metabolites is incomplete.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Approximately 71% of the rotigotine dose is excreted in urine and a smaller part of about 23% is excreted in faeces.</p><p>The clearance of rotigotine after transdermal administration is approximately 10 l/min and its overall elimination half-life is 5 to 7 hours. The pharmacokinetic profile shows a biphasic elimination with an initial half-life of about 2 to 3 hours.</p><p>&nbsp;</p><p>Because the patch is administered transdermally, no effect of food and gastrointestinal conditions is expected.</p><p>&nbsp;</p><p><u>Special patient groups </u></p><p><u>&nbsp;</u></p><p>Because therapy with Neupro is initiated at a low dose and gradually titrated according to clinical tolerability to obtain the optimum therapeutic effect, adjustment of the dose based on gender, weight, or age is not necessary.</p><p>&nbsp;</p><p><em>Hepatic and renal impairment</em></p><p>&nbsp;</p><p>In subjects with moderate hepatic impairment or mild to severe renal impairment, no relevant increases of rotigotine plasma levels were observed. Neupro was not investigated in patients with severe hepatic impairment.</p><p>Plasma levels of conjugates of rotigotine and its desalkyl metabolites increase with impaired renal function. However, a contribution of these metabolites to clinical effects is unlikely.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.3&nbsp;&nbsp;&nbsp; Preclinical safety data</strong></p><p>&nbsp;</p><p>In repeated dose and long-term toxicity studies, the major effects were associated with the dopamine agonist related pharmacodynamic effects and the consequent decrease of prolactin secretion.</p><p>After a single dose of rotigotine, binding to melanin-containing tissues (i.e., eyes) in the pigmented rat and monkey was evident, but was slowly cleared over the 14-day observation period.</p><p>Retinal degeneration was observed by transmission microscopy at a dose equivalent to 2.8 times the maximum recommended human dose on a mg/m&sup2; basis in a 3-month study in albino rats. The effects were more pronounced in female rats. Additional studies to further evaluate the specific pathology have not been performed. Retinal degeneration was not observed during the routine histopathological evaluation of the eyes in any of the toxicology studies in any species used. The relevance of these findings to humans is not known.</p><p>In a carcinogenicity study, male rats developed Leydig cell tumours and hyperplasia. Malignant tumours were noted predominantly in the uterus of mid- and high-dose females. These changes are well-known effects of dopamine agonists in rats after life-long therapy and assessed as not relevant to man.</p><p>The effects of rotigotine on reproduction have been investigated in rats, rabbits and mice. Rotigotine was not teratogenic in all three species, but was embryotoxic in rats and mice at materno-toxic doses. Rotigotine did not influence male fertility in rats, but clearly reduced female fertility in rats and mice, because of the effects on prolactin levels which are particularly significant in rodents.</p><p>&nbsp;</p><p>Rotigotine did not induce gene mutations in the Ames test, but did show effects in the <em>in vitro </em>Mouse Lymphoma Assay with metabolic activation and weaker effects without metabolic activation. This mutagenic effect could be attributed to a clastogenic effect of rotigotine. This effect was not</p><p>confirmed <em>in vivo </em>in the Mouse Micronucleus Test in the rat Unscheduled DNA Synthesis (UDS) test. Since it ran more or less parallel with a decreased relative total growth of the cells, it may be related</p><p>to a cytotoxic effect of the compound. Therefore, the relevance of the one positive <em>in vitro</em></p><p>mutagenicity test is not known.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.1&nbsp;&nbsp;&nbsp; List of excipients</strong></p><p>&nbsp;</p><p><u>Backing layer</u></p><p>&nbsp;</p><p>Polyester film, siliconized, aluminized,</p><p>colour coated with a pigment (titanium dioxide (E171), pigment yellow 95, pigment red 166) layer and imprinted (pigment red 144, pigment yellow 95, pigment black 7).</p><p>&nbsp;</p><p><u>Self adhesive matrix layer</u></p><p><u>&nbsp;</u></p><p>Poly(dimethylsiloxane, trimethylsilyl silicate)-copolymerisate,</p><p>Povidone K90,</p><p>Sodium metabisulphite (E223),</p><p>ascorbyl palmitate (E304) and</p><p>DL-&alpha;-tocopherol (E307).</p><p><u>&nbsp;</u></p><p><u>Release liner</u></p><p>&nbsp;</p><p>Transparent fluoropolymer coated polyester film.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.2&nbsp;&nbsp;&nbsp; Incompatibilities</strong></p><p>&nbsp;</p><p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                6.3	Shelf life

30 months.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.4&nbsp;&nbsp;&nbsp; Special precautions for storage</strong></p><p>&nbsp;</p><p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.5&nbsp;&nbsp;&nbsp; Nature and contents of container</strong></p><p>&nbsp;</p><p>Peel off sachet in a cardboard carton: One side is composed of an ethylene copolymer (innermost layer), an aluminium foil, low density polyethylene film and paper; the other side is composed of polyethylene (innermost layer), aluminium, ethylene copolymer and paper.</p><p>&nbsp;</p><p>The carton contains 7 or 28 transdermal patches, individually sealed in sachets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.6&nbsp;&nbsp;&nbsp; Special precaution for disposal</strong></p><p>&nbsp;</p><p>After use the patch still contains active substance. After removal, the used patch should be folded in half, adhesive side inwards so that the matrix layer is not exposed, placed in the original sachet and then discarded. Any used or unused patches should be disposed of in accordance with local requirements or returned to the pharmacy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	UCB Pharma S.A.
	Allée de la Recherche 60
	B-1070 Bruxelles
	Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                {06/2018}
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>